Zimmer Biomet/$ZBH
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Zimmer Biomet
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Ticker
$ZBH
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
17,000
ISIN
US98956P1021
Website
Zimmer Biomet Metrics
BasicAdvanced
$19B
21.11
$4.51
0.78
$0.96
1.01%
Price and volume
Market cap
$19B
Beta
0.78
52-week high
$116.37
52-week low
$89.22
Average daily volume
2M
Dividend rate
$0.96
Financial strength
Current ratio
2.436
Quick ratio
1.271
Long term debt to equity
53.018
Total debt to equity
59.058
Dividend payout ratio (TTM)
21.28%
Interest coverage (TTM)
6.61%
Profitability
EBITDA (TTM)
2,554.4
Gross margin (TTM)
71.20%
Net profit margin (TTM)
11.86%
Operating margin (TTM)
20.04%
Effective tax rate (TTM)
12.91%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
4.42%
Return on equity (TTM)
7.32%
Valuation
Price to earnings (TTM)
21.108
Price to revenue (TTM)
2.491
Price to book
1.52
Price to tangible book (TTM)
-17.74
Price to free cash flow (TTM)
16.957
Free cash flow yield (TTM)
5.90%
Free cash flow per share (TTM)
561.12%
Dividend yield (TTM)
1.01%
Forward dividend yield
1.01%
Growth
Revenue change (TTM)
3.30%
Earnings per share change (TTM)
-2.33%
3-year revenue growth (CAGR)
3.77%
10-year revenue growth (CAGR)
5.18%
3-year earnings per share growth (CAGR)
62.92%
10-year earnings per share growth (CAGR)
1.46%
10-year dividend per share growth (CAGR)
0.87%
What the Analysts think about Zimmer Biomet
Analyst ratings (Buy, Hold, Sell) for Zimmer Biomet stock.
Zimmer Biomet Financial Performance
Revenues and expenses
Zimmer Biomet Earnings Performance
Company profitability
Zimmer Biomet News
AllArticlesVideos
Final Trades: Uber, Delta, Zimmer Holdings and Boeing
CNBC Television·2 hours ago
We pay attention to policy and patients, says Zimmer Biomet CEO Ivan Tornos
CNBC Television·2 months ago
Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys
24/7 Wall Street·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jul31
Zimmer Biomet
Dividend·Payment
$0.24Per share
FAQs
What’s the current market cap for Zimmer Biomet stock?
Zimmer Biomet (ZBH) has a market cap of $19B as of July 11, 2025.
What is the P/E ratio for Zimmer Biomet stock?
The price to earnings (P/E) ratio for Zimmer Biomet (ZBH) stock is 21.11 as of July 11, 2025.
Does Zimmer Biomet stock pay dividends?
Yes, the Zimmer Biomet (ZBH) stock pays dividends to shareholders. As of July 11, 2025, the dividend rate is $0.96 and the yield is 1.01%. Zimmer Biomet has a payout ratio of 21.28% on a trailing twelve-month basis.
When is the next Zimmer Biomet dividend payment date?
The next Zimmer Biomet (ZBH) dividend payment is scheduled for July 31, 2025.
What is the beta indicator for Zimmer Biomet?
Zimmer Biomet (ZBH) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.